Investing
Proceeds From Sale And Maturity Of Available For Sale Securities
Neurocrine Biosciences Proceeds From Sale And Maturity Of Available For Sale Securities decreased by 3.2% to $259.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.0%, from $298.10M to $259.20M. Over 4 years (FY 2021 to FY 2025), Proceeds From Sale And Maturity Of Available For Sale Securities shows an upward trend with a 11.8% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ3 2018
Last reportedQ1 2026May 5, 2026
How to read this metric
High proceeds indicate active portfolio rebalancing or the liquidation of assets to meet liquidity needs.
Detailed definition
This represents the cash inflows resulting from the sale, redemption, or maturity of investment securities classified as...
Peer comparison
Standard for insurance companies; reflects the liquidity and turnover of the investment asset base.
Metric ID:
investing_proceeds_from_sale_and_maturity_of_available_f_0efd08Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.90M | $159.70M | $174.00M | $176.50M | $101.10M | $71.20M | $162.20M | $203.90M | $204.70M | $273.00M | $290.80M | $276.30M | $175.10M | $265.30M | $250.80M | $298.10M | $298.60M | $225.00M | $267.70M | $259.20M |
| QoQ Change | — | -21.3% | +9.0% | +1.4% | -42.7% | -29.6% | +127.8% | +25.7% | +0.4% | +33.4% | +6.5% | -5.0% | -36.6% | +51.5% | -5.5% | +18.9% | +0.2% | -24.6% | +19.0% | -3.2% |
| YoY Change | — | — | — | — | -50.2% | -55.4% | -6.8% | +15.5% | +102.5% | +283.4% | +79.3% | +35.5% | -14.5% | -2.8% | -13.8% | +7.9% | +70.5% | -15.2% | +6.7% | -13.0% |
Range$71.20M – $298.60M
CAGR+5.3%
Avg YoY Growth+26.9%
Median YoY Growth+2.0%
Proceeds From Sale And Maturity Of Available For Sale Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's proceeds from sale and maturity of available for sale securities?
- Neurocrine Biosciences (NBIX) reported proceeds from sale and maturity of available for sale securities of $259.20M in Q1 2026.
- How has Neurocrine Biosciences's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Neurocrine Biosciences's proceeds from sale and maturity of available for sale securities decreased by 13.0% year-over-year, from $298.10M to $259.20M.
- What is the long-term trend for Neurocrine Biosciences's proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's proceeds from sale and maturity of available for sale securities has grown at a 11.8% compound annual growth rate (CAGR), from $697.90M to $1.09B.
- What does proceeds from sale and maturity of available for sale securities mean?
- Cash received from selling or maturing investment securities.